MedTrace Logo

Monitoring and Preventing Hydroxychloroquine, Plaquenil, Toxicity.

NCT03316092 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2017-10-23

No results posted yet for this study

Summary

Oral Hydoxychloroquine is a very popular medication widely used by patients with rheumatoid arthritis, Systemic Lupus Erythematosus and other diseases. Ocular side effects of this medication are very serious and causes loss of central vision. In most patients these side effects are dose related, cumulative. This means that the risk of side effects would increase in all patients with continued use of the medication. In few people use of the medication would not be recommended if they have some bilateral macular problems. This is because the side effects of this medication does cause serious degredation of the macula in both eyes.

Conditions

  • Hydroxychloroquine Toxicity

Interventions

DIAGNOSTIC_TEST

optical coherence tomography

screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine

Sponsors & Collaborators

  • Dr. S.S. Michel Clinic

    lead OTHER

Principal Investigators

  • shawkat s michel, FRCS Ed · Dr. S.S. Michel Clinic

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-07
Primary Completion
2017-01-10
Completion
2017-10-10

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03316092 on ClinicalTrials.gov